Baillie Gifford & Co
WX

Baillie Gifford & Co’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Baillie Gifford & Co’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,428
Closed -$321K – 213
2015
Q3 		$321K Buy
7,428
+639
+9% +$27K ﹤0.01% 190
2015
Q2 		$287K Sell
6,789
-55
-0.8% -$2.32K ﹤0.01% 191
2015
Q1 		$265K Buy
6,844
+391
+6% +$15.1K ﹤0.01% 195
2014
Q4 		$217K Buy
6,453
+4,020
+165% +$142K ﹤0.01% 194
2014
Q3 		$85K Buy
+2,433
New +$83.4K ﹤0.01% 200

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Baillie Gifford & Co's WX Position: Q4 2015 in Review

Baillie Gifford & Co sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 7,428 shares — an estimated $321K sold.

Baillie Gifford & Co first reported a position in WX in Q3 2014 and held it in 5 quarters. The position peaked at $321K in Q3 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Baillie Gifford & Co reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Baillie Gifford & Co sold 7,428 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $321K.
  • Baillie Gifford & Co first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2014 and held it in 5 quarters.
  • Baillie Gifford & Co's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $321K in Q3 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Baillie Gifford & Co's 13F filing for Q4 2015, filed 8 Feb 2016.